AS-IV (dose 10 and 20 μg/mL) can also inhibit tumor metastasis by inhibiting TGF-β1 and inducing EMT to inhibit the PI3K/AKT/NF-κB pathway in BGC-823 and MKN-74 cells (Zhu et al., 2018). Here, AKT1 is linked to neoplasm.